Insider · CIK 0001296999

Arkowitz David

Reports to the SEC for 7 companies · LEXINGTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001296999

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-11-20	IBIOiBio, Inc. · Stock Option (right to buy)A Award	Director	AAward	+13.5K sh	—	—	13,500
2025-06-30	KINETA, INC./DEStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−12.5K sh	—	—	0
2025-06-30	KINETA, INC./DEStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2025-06-30	KINETA, INC./DED Disposition to Issuer	Director	DDisposition to Issuer	−16.6K sh	—	—	0
2025-06-25	KINETA, INC./DEA Award	Director	AAward	+6,000 sh	—	—	18,141
2025-06-23	KINETA, INC./DEStock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−12.5K sh	—	—	0
2025-06-23	KINETA, INC./DEF Tax Payment	Director	FTax Payment	−4,706 sh	$0.26	−$1,223.56	12,141
2025-06-23	KINETA, INC./DEM Exercise/Conversion	Director	MExercise/Conversion	+12.5K sh	$0.61	+$7,637.5	16,847
2025-01-10	IBIOiBio, Inc.P Purchase	Director	PPurchase	+18.4K sh	$2.72	+$50K	18,382
2024-11-21	IBIOiBio, Inc. · Stock Option (right to buy)A Award	Director	AAward	+12.6K sh	—	—	12,600
2024-09-04	KINETA, INC./DEStock Option (Right to Buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2024-02-16	MCRBSeres Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,939 sh	$1.08	−$4,254.12	182,442
2024-02-15	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−10.6K sh	—	—	31,875
2024-02-15	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+10.6K sh	—	—	186,381
2024-02-14	MCRBSeres Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+214K sh	—	—	213,750
2024-02-14	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+35.6K sh	—	—	35,625
2024-02-14	MCRBSeres Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+288K sh	—	—	287,905
2023-10-30	MCRBSeres Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−4,066 sh	$1.35	−$5,489.1	175,756
2023-10-27	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−13.2K sh	—	—	13,209
2023-10-27	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+13.2K sh	—	—	179,822
2023-04-27	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+26.4K sh	—	—	26,418
2023-04-27	MCRBSeres Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+42.5K sh	—	—	166,613
2023-04-12	KINETA, INC./DEStock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2023-04-12	KINETA, INC./DEStock Option (Right to Buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2023-03-08	F-star Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2023-03-08	F-star Therapeutics, Inc.U Disposition from Tender	Director	UDisposition from Tender	−8,386 sh	$7.12	−$59.7K	0
2023-03-08	F-star Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2023-02-03	MCRBSeres Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+85K sh	—	—	85,000
2023-02-03	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+42.5K sh	—	—	42,500
2022-10-27	MCRBSeres Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+42.5K sh	—	—	112,992
2022-07-05	MCRBSeres Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+63.5K sh	$3.15	+$200K	65,492
2022-06-17	F-star Therapeutics, Inc.Stock OptionA Award	Director	AAward	+20K sh	—	—	20,000
2022-06-15	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,000 sh	—	—	0
2022-06-15	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,000 sh	—	—	70,492
2022-02-04	MCRBSeres Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+190K sh	—	—	190,000
2021-06-04	F-star Therapeutics, Inc.Stock OptionA Award	Director	AAward	+20K sh	—	—	20,000
2021-06-02	KINETA, INC./DEStock Option (Right to Buy)A Award	Director	AAward	+14.8K sh	—	—	14,800
2021-06-01	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+5,000 sh	—	—	5,000
2021-06-01	MCRBSeres Therapeutics, Inc. · Stock Options (right to buy)A Award	Chief Financial Officer	AAward	+270K sh	—	—	270,000
2021-05-10	Flexion Therapeutics IncS Sale	Chief Financial Officer	SSale	−2,229 sh	$7.23	−$16.1K	220,719
2021-03-01	Flexion Therapeutics IncA Award	Chief Financial Officer	AAward	+30K sh	—	—	181,048
2021-03-01	Flexion Therapeutics IncA Award	Chief Financial Officer	AAward	+41.9K sh	—	—	222,948
2021-03-01	Flexion Therapeutics IncStock option (right to buy)A Award	Chief Financial Officer	AAward	+20K sh	—	—	20,000
2021-01-05	Flexion Therapeutics IncS Sale	Chief Financial Officer	SSale	−6,073 sh	$11.13	−$67.6K	151,048
2020-12-22	KINETA, INC./DEA Award	Director	AAward	+4,347 sh	$23.00	+$100K	4,347
2020-11-20	F-star Therapeutics, Inc.Stock Option (right to buy)J Other	Director	JOther	−7,500 sh	—	—	0
2020-11-20	F-star Therapeutics, Inc.Stock Option (right to buy)J Other	Director	JOther	−10K sh	—	—	0
2020-11-20	F-star Therapeutics, Inc.Stock Option (right to buy)J Other	Director	JOther	−5,500 sh	—	—	0
2020-11-20	F-star Therapeutics, Inc.Warrant (right to buy)J Other	Director	JOther	−4,386 sh	—	—	0
2020-11-20	F-star Therapeutics, Inc.Stock Option (right to buy)J Other	Director	JOther	−5,500 sh	—	—	0

Recent filings

Accepted (ET)
Nov 244
Arkowitz David0001104659-25-115407
SEC(opens sec.gov)
Jul 24
Arkowitz David0000950170-25-092994
SEC(opens sec.gov)
Jun 254
Arkowitz David0000950170-25-090137
SEC(opens sec.gov)
Jan 134
Arkowitz David0001104659-25-003061
SEC(opens sec.gov)
Nov 254
Arkowitz David0001104659-24-122589
SEC(opens sec.gov)
Sep 54
Arkowitz David0000950170-24-104011
SEC(opens sec.gov)
Feb 164
Arkowitz David0000950170-24-016687
SEC(opens sec.gov)
Oct 314
Arkowitz David0000899243-23-020077
SEC(opens sec.gov)

Companies

Address

C/O AMAG PHARMACEUTICALS, INC. 100 HAYDEN AVENUE

LEXINGTON, MA, 02421